Cell and Gene Therapy Investment Trends

Cell and gene therapies are currently among the hottest investments in the biotech space, both in the public and private markets. In this episode, Back Bay’s Managing Director and host Pete Bak, PhD is joined by Kyle O’Neil and Brendan Wang, who are returning to the podcast after attending the 2021 Cell and Gene Meeting on the Mesa. Tune in to hear their discussion on emerging investment themes and which ones were key topics of discussion at this year’s conference.Topics include:The next generation of gene-editing technologyCRISPR 2.0Off-target effectsNovel nucleasesPAM sequencesAutologous and Allogeneic CAR-T cell therapyEx vivo vs. in vivo approachesThe business model on gene therapiesFiguring out manufacturing capabilities firstHow to tap into larger marketsBuilding businesses around small monogenic diseasesLearn more, read Bay Life Science Advisors' latest white paper on gene therapy innovation here.Make sure to subscribe to The Life Science Report podcast and follow Back Bay Life Science Advisors on LinkedIn.Thank you for joining us.